Amgen and UCB have announced positive high quality results from the pivotal Phase 3 placebo-controlled study evaluatIng the efficiency and safety of romosozumab in treating men with osteoporosis (BRIDGE) trial. Read More »

The National Association of Chain Drug Stores (NACDS) held its eighth annual RxIMPACT Day on Capitol Hill this week to showcase grassroots activism and political engagement. Read More »

The U.S. Senate this week passed the National Association of Chain Drug Stores-backed Ensuring Patient Access and Effective Drug Enforcement Act of 2016 (S. 483). Read More »

Incyte Corp. has announced that it will be presenting 10 abstracts at the American Association for Cancer Research (AACR) Annual Meeting 2016 that will feature data from its emerging development portfolio. Read More »

The American Pharmacists association (APhA) has announced that its House of Delegates voted to enact a new policy regarding the labeling and measurement of oral liquid medications at the APhA Annual Meeting in Baltimore, Maryland. Read More »

Astellas Pharm Inc. announced this week that it has named a Nadeshiko Brand component by the Ministry of Economy, Trade and Industry (METI) and the Tokyo Stock Exchange (TSE) for its excellence in the promotion and involvement of women in the workplace. Read More »

Sanofi and Regeneron Pharmaceuticals recently announced that both companies strongly oppose the U.S. District Court jury decision for two patents involving Amgen antibodies designed to target PCSK9 (proprotein canvertase subtilisin/kexin type 9) that have been deemed valid. Read More »

Orexigen Therapeutics and Takeda Pharmaceuticals U.S.A., a subsidiary of Takeda Pharmaceutical Co., announced earlier this week that they have agreed on terms to terminate the Amended and Restated Collaboration Agreement for CONTRAVE (naltrexone HCI/bupropion HCI). All rights to the medication will belong to Orexigen. Read More »

Walgreens and OptumRx have announced a partnership that will result in the creation of a new pharmacy solution program aimed at changing prescription drug needs to benefit the consumer and help employers, health plans and members receive higher health outcomes and save more. Read More »

The Takeda Pharmaceutical Co. and Frazier Healthcare Partners recently launched Outpost Medicine, a new company in the biopharmaceutical field that will focus on developing new treatment options for urologic and gynecologic diseases and disorders. Read More »

Pfizer has announced that it will be presenting new data based on the research of tofacitinib in ulcerative colitis (UC) and Crohn’s disease at the 11th Congress of ECCO, which is scheduled for March 16-19 in Amsterdam. Read More »

The CVS Health Foundation has announced a second round of grants in collaboration with the Campaign for Tobacco-Free Kids that will be awarded through the grant program known as “Making the Next Generation Tobacco-Free.” Read More »

The Center for Disease Control (CDC) has released new guidelines that provide recommendations that will enhance the care and safety of patients that have been prescribed opioids for chronic pain. Read More »

Aetna made an announcement last week naming New Century Health (NCH) a preferred national solution partner for oncology. Read More »

Sanofi and Regeneron Pharmaceuticals announced that the Phase 3 study of monotherapies set to demonstrate the superiority of sarilumab to adalimumab when treating active rheumatoid arthritis (RA) has met its primary goal. Read More »

Pfizer today released its 2015 integrated annual review, which is an in-depth look at the company’s financial, social and environmental performance. Read More »

Amgen has announced that its supplemental Biologics License Application (sBLA) for the extended use of Enbrel (etanercept) in the treatment of chronic severe plaque psoriasis in pediatric patients has been accepted for review by the U.S. Food and Drug Administration (FDA). Read More »

Pharmacyclics LLC, an AbbVie company, and Janssen Biotech Inc., developers of the award-winning drug Imbruvica (ibrutinib) aim to continue enhancing the cancer-fighting drug’s clinical meaningfulness. Read More »

AstraZeneca and MedImmune have announced that the U.S. Food and Drug Administration (FDA) has granted MEDI-551, an anti-CD19 monoclonal antibody, Orphan Drug Designation. Read More »

Pfizer recently published the results to its Phase 3 study of BeneFIX Coagulation Factor IX (recombinant) 100 IU/kg prophylaxis compared to on-demand treatment for patients with moderately severe or severe hemophilia B. Read More »